1.2. Pediatrics
Fluoroquinolones are not drugs of choice in pediatric patients due to an increased incidence of musculoskeletal adverse reactions, including arthralgias and events related to surrounding joints and tissues10. However, ciprofloxacin and levofloxacin have been evaluated for use in pediatric patients and are FDA-approved for use in select circumstances. Recommended dosage guidelines for fluoroquinolones in pediatric patients are summarized in Table 2.
| Drug Name | Treatment Indication | Maximum Recommended Dosage |
|---|---|---|
| ciprofloxacin | complicated urinary tract infection (UTI) or pyelonephritis | 10-20 mg/kg orally every 12 hours (not to exceed 750 mg/dose) |
| inhalational anthrax (postexposure prophylaxis) | 15 mg/kg orally every 12 hours (not to exceed 500 mg/dose) | |
| plague | 15 mg/kg orally every 8-12 hours (not to exceed 500 mg/dose) | |
| levofloxacin | inhalational anthrax (postexposure prophylaxis) |
Greater than or equal to 6 months of age and less than 50 kg: 8 mg/kg orally every 12 hours (not to exceed 250 mg/dose) Greater than or equal to 6 months of age and greater than 50 kg: 500 mg orally once daily |
| plague |
Greater than or equal to 6 months of age and less than 50 kg: 8 mg/kg orally every 12 hours (not to exceed 250 mg/dose) Greater than or equal to 6 months of age and greater than 50 kg: 500 mg orally once daily |